skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
previous page 1 Resultados 2 3 4 5 next page
Mostrar Somente
Refinado por: Nome da Publicação: Annals Of Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
11
LINE-1 hypomethylation is a specific aberration in human hepatocellular carcinomas and correlates with shorter overall survival and CIMP-phenotypes
LINE-1 hypomethylation is a specific aberration in human hepatocellular carcinomas and correlates with shorter overall survival and CIMP-phenotypes
Material Type:
Artigo 		Adicionar ao Meu Espaço

LINE-1 hypomethylation is a specific aberration in human hepatocellular carcinomas and correlates with shorter overall survival and CIMP-phenotypes

Anwar, S.L. ; Vogel, A. ; Lehmann, U.

Annals of oncology, 2018-09, Vol.29, p.vi5-vi5 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
12
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

Folprecht, G. ; Pericay, C. ; Saunders, M.P. ; Thomas, A. ; Lopez Lopez, R. ; Roh, J.K. ; Chistyakov, V. ; Höhler, T. ; Kim, J.-S. ; Hofheinz, R.-D. ; Ackland, S.P. ; Swinson, D. ; Kopp, M. ; Udovitsa, D. ; Hall, M. ; Iveson, T. ; Vogel, A. ; Zalcberg, J.R.

Annals of oncology, 2016-07, Vol.27 (7), p.1273-1279 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
13
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]
Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]
Material Type:
Artigo 		Adicionar ao Meu Espaço

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Vogel, A. ; Cervantes, A. ; Chau, I. ; Daniele, B. ; Llovet, J.M. ; Meyer, T. ; Nault, J.-C. ; Neumann, U. ; Ricke, J. ; Sangro, B. ; Schirmacher, P. ; Verslype, C. ; Zech, C.J. ; Arnold, D. ; Martinelli, E.

Annals of oncology, 2022-06, Vol.33 (6), p.666-666 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
14
Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Material Type:
Artigo 		Adicionar ao Meu Espaço

Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Vogel, A. ; Cervantes, A. ; Chau, I. ; Daniele, B. ; Llovet, J.M. ; Meyer, T. ; Nault, J.-C. ; Neumann, U. ; Ricke, J. ; Sangro, B. ; Schirmacher, P. ; Verslype, C. ; Zech, C.J. ; Arnold, D. ; Martinelli, E.

Annals of oncology, 2019-05, Vol.30 (5), p.871-873 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
15
Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Material Type:
Artigo 		Adicionar ao Meu Espaço

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Finn, R.S. ; Kudo, M. ; Cheng, A.-L. ; Wyrwicz, L. ; Ngan, R. ; Blanc, J.F. ; Baron, A.D. ; Vogel, A. ; Ikeda, M. ; Piscaglia, F. ; Han, K.-H. ; Qin, S. ; Minoshima, Y. ; Kanekiyo, M. ; Ren, M. ; Dairiki, R. ; Tamai, T. ; Dutcus, C.E. ; Funahashi, Y. ; Evans, T.R.J.

Annals of oncology, 2018-10, Vol.29, p.viii17-viii18 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
16
FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome
FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome
Material Type:
Artigo 		Adicionar ao Meu Espaço

FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

Schmoll, H. ; Garlipp, B. ; Junghanß, C. ; Vogel, A. ; Kaiser, U. ; Florschütz, A. ; Kanzler, S. ; Hannig, C. ; Meinert, F. ; Cygon, F. ; Stein, A.

Annals of oncology, 2018-06, Vol.29, p.v108-v108 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
17
Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress
Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Qin, S. ; Finn, R. ; Kudo, M. ; Meyer, T. ; Vogel, A. ; Ducreux, M. ; Macarulla, T. ; Tomasello, G. ; Boisserie, F. ; Hou, J. ; Li, C. ; Song, J. ; Zhu, A.

Annals of oncology, 2018-06, Vol.29, p.v51-v51 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
18
Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies

Kang, Y.-K. ; Kudo, M. ; Lim, H.-Y. ; Hsu, C.-H. ; Vogel, A. ; Brandi, G. ; Cheng, R. ; Carton, I. ; Abada, P. ; Hsu, Y. ; Zhu, A. ; Yen, C.-J.

Annals of oncology, 2018-11, Vol.29, p.ix46-ix46 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
19
Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
Material Type:
Artigo 		Adicionar ao Meu Espaço

Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress

Qin, S. ; Finn, R.S. ; Kudo, M. ; Meyer, T. ; Vogel, A. ; Ducreux, M.P. ; Macarulla, T.M. ; Tomasello, G. ; Boisserie, F. ; Hou, J. ; Li, C. ; Song, J. ; Zhu, A.X.

Annals of oncology, 2018-10, Vol.29, p.viii264-viii265 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
20
Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program
Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

Moehler, M. ; Maderer, A. ; Thuss-Patience, P. ; Brenner, B. ; Hecker, J. ; Muñoz, F. Longo ; Meiler, J. ; Ettrich, T. ; Hofheinz, R. ; Al-Batran, S. ; Vogel, A. ; Mueller, L. ; Lutz, M. ; Borchert, K. ; Greil, R. ; Alsina, M. ; Karatas, A. ; Van Cutsem, E. ; Keller, R. ; Larcher-Senn, J. ; Lorenzen, S.

Annals of oncology, 2018-06, Vol.29, p.v103-v103 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
previous page 1 Resultados 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (91)

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.